Respiratory News and Research RSS Feed - Respiratory News and Research

Kaleo announces U.S. availability of EVZIO for emergency treatment of opioid overdose

Kaleo announces U.S. availability of EVZIO for emergency treatment of opioid overdose

Kaleo, a privately-held pharmaceutical company headquartered in Richmond, Virginia, today announced the United States (U.S.) commercial availability of EVZIO for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. [More]
Experts release position statement on electronic cigarettes

Experts release position statement on electronic cigarettes

Experts from the world's leading lung organizations have released a position statement on electronic cigarettes, focusing on their potential adverse effects on human health and calling on governments to ban or restrict their use until their health impacts are better known. [More]
New study reveals unique health challenges faced by urban Aboriginal people in Canada

New study reveals unique health challenges faced by urban Aboriginal people in Canada

For the first time, researchers have access to detailed information about how an urban Aboriginal population in Canada uses health care. A new study, called Our Health Counts, uses this health database to clearly demonstrate the unique challenges faced by urban Aboriginal people in Canada - according to researchers at St. Michael's Hospital. [More]
Depressed COPD patients have difficulty in sticking to pulmonary rehabilitation program

Depressed COPD patients have difficulty in sticking to pulmonary rehabilitation program

Researchers from The Miriam Hospital have found that people with Chronic obstructive pulmonary disease (COPD) who are also depressed have difficulty sticking to a pulmonary rehabilitation program. [More]
Study identifies hearing requirements of British soldiers fighting on the frontline

Study identifies hearing requirements of British soldiers fighting on the frontline

University of Southampton researchers, with assistance from the Ministry of Defence, have conducted the first study to identify the hearing requirements of British soldiers fighting on the frontline. [More]
National prevention strategy for a healthy lifestyle

National prevention strategy for a healthy lifestyle

Cardiovascular diseases (CVDs), cancer, diabetes and chronic respiratory disorders - the incidence of these non-communicable diseases (NCDs) is constantly rising in industrialised countries. [More]
Mercy Memorial Hospital System signs LOI to join Promedica

Mercy Memorial Hospital System signs LOI to join Promedica

Mercy Memorial Hospital System signed a letter of intent to join ProMedica, a not-for-profit, multi-hospital system based in Toledo, Ohio. [More]
Study gives parents, doctors new options to treat children with eczema

Study gives parents, doctors new options to treat children with eczema

The number of children with atopic dermatitis, often referred to as eczema, is on the rise. Some estimate that one in five children in the U.S. now suffers from the painful, itchy skin condition. In an effort to control their symptoms, many children are prescribed powerful medications like immunosuppressants or topical steroids. [More]
First report of spinal cord mass arising from spinal cord cell transplantation

First report of spinal cord mass arising from spinal cord cell transplantation

A spinal mass was identified in a young woman with complete spinal cord injury 8 years after she had undergone implantation of olfactory mucosal cells in the hopes of regaining sensory and motor function. [More]
Scientists uncover mechanisms that can protect against lethal bacteria

Scientists uncover mechanisms that can protect against lethal bacteria

An important development in understanding how the bacterium that causes pneumonia, meningitis and septicaemia remains harmlessly in the nose and throat has been discovered at the University of Liverpool's Institute of Infection and Global Health. [More]
Study documents impact of behavioural factors on life expectancy

Study documents impact of behavioural factors on life expectancy

Live longer thanks to fruit, an active lifestyle, limited alcohol and no cigarettes. This is the conclusion of a study by public health physicians at the University of Zurich who documented for the first time the impact of behavioural factors on life expectancy in numbers. The results are to be taken over into prevention and health counselling in primary care. [More]
UC Riverside discovery could lead to future development of needle-free vaccines

UC Riverside discovery could lead to future development of needle-free vaccines

Ripping a page from the Star Trek script, specialized cells of the barrier that lines the inside of the intestines and airways of humans have invoked a biological version of Captain Kirk's famous command "shields up" as a first defense against invading microbes. [More]

New test for TB could improve speed and accuracy of diagnosis for deadliest diseases

A new test for tuberculosis (TB) could dramatically improve the speed and accuracy of diagnosis for one of the world's deadliest diseases, enabling health care providers to report results to patients within minutes, according to a study published this week in the journal Angewandte Chemie. [More]
Military physicians will soon pick up joysticks to save lives of children

Military physicians will soon pick up joysticks to save lives of children

Military physicians will soon pick up joysticks instead of textbooks to learn skills that could save lives of children with serious health threats. [More]
FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL). [More]
WHO presents new framework to eliminate TB in 33 countries

WHO presents new framework to eliminate TB in 33 countries

The World Health Organization today, together with the European Respiratory Society, presented a new framework to eliminate tuberculosis (TB) in countries with low levels of the disease. Today there are 33 countries and territories where there are fewer than 100 TB cases per million population. [More]
FDA grants Fast Track designation to Akashi Therapeutics' HT-100 for treatment of DMD

FDA grants Fast Track designation to Akashi Therapeutics' HT-100 for treatment of DMD

Akashi Therapeutics, Inc., announced today that the U.S. Food and Drug Administration has granted Fast Track designation to the company's most advanced product candidate, HT-100 (delayed-release halofuginone), an orally available, small molecule drug candidate intended to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with DMD. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
Study finds deployment-related respiratory symptoms in veterans returning from Iraq, Afghanistan

Study finds deployment-related respiratory symptoms in veterans returning from Iraq, Afghanistan

In a new study of the causes underlying respiratory symptoms in military personnel returning from duty in Iraq and Afghanistan, a large percentage of veterans had non-specific symptoms that did not lead to a specific clinical diagnosis. [More]
Forest Laboratories completes acquisition of Furiex Pharmaceuticals

Forest Laboratories completes acquisition of Furiex Pharmaceuticals

Actavis plc today announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc. in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval. [More]